These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18989355)

  • 1. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice.
    Kulu Y; Dorfman JD; Kuruppu D; Fuchs BC; Goodwin JM; Fujii T; Kuroda T; Lanuti M; Tanabe KK
    Cancer Gene Ther; 2009 Apr; 16(4):291-7. PubMed ID: 18989355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis.
    Eveno C; Mojica K; Ady JW; Thorek DL; Longo V; Belin LJ; Gholami S; Johnsen C; Zanzonico P; Chen N; Yu T; Szalay AA; Fong Y
    Surgery; 2015 Feb; 157(2):331-7. PubMed ID: 25616946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.
    Lambright ES; Kang EH; Force S; Lanuti M; Caparrelli D; Kaiser LR; Albelda SM; Molnar-Kimber KL
    Mol Ther; 2000 Oct; 2(4):387-93. PubMed ID: 11020355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer.
    Stanziale SF; Stiles BM; Bhargava A; Kerns SA; Kalakonda N; Fong Y
    Hum Gene Ther; 2004 Jun; 15(6):609-18. PubMed ID: 15212719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
    Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
    FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
    Spear MA; Sun F; Eling DJ; Gilpin E; Kipps TJ; Chiocca EA; Bouvet M
    Cancer Gene Ther; 2000 Jul; 7(7):1051-9. PubMed ID: 10917208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus.
    Shikano T; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Nishikawa Y; Shirota T; Yamada S; Fujii T; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
    Curr Cancer Drug Targets; 2011 Jan; 11(1):111-22. PubMed ID: 21062239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
    Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
    Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.
    Nakatake R; Kaibori M; Nakamura Y; Tanaka Y; Matushima H; Okumura T; Murakami T; Ino Y; Todo T; Kon M
    Cancer Sci; 2018 Mar; 109(3):600-610. PubMed ID: 29288515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
    Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
    Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
    Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
    Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes.
    Kanzaki A; Kasuya H; Yamamura K; Sahin TT; Nomura N; Shikano T; Shirota T; Tan G; Fukuda S; Misawa M; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Nomoto S; Takeda S; Kodera Y; Nakao A
    Cancer Gene Ther; 2012 Apr; 19(4):292-8. PubMed ID: 22281756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.